Related Experiment Video
Updated: Sep 16, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network
Ao Shi1,2, Yuan Shu3, Joe El Haddad1,2
1Faculty of Medicine, St. George's, University of London, London, UK.
Dermatology and Therapy
|July 5, 2025
Summary
Bimekizumab demonstrated superior efficacy and safety for plaque psoriasis, significantly reducing cardiovascular events. Ixekizumab showed efficacy but may increase cardiovascular risk, warranting caution in its use.
Area of Science:
- Dermatology
- Immunology
- Cardiovascular Medicine
- Nephrology
Background:
- Systemic immunomodulatory treatments are used for chronic plaque psoriasis.
- These treatments may impact cardiovascular and renal outcomes.
- A network meta-analysis was conducted to compare systemic treatments for plaque psoriasis.
Purpose of the Study:
- To compare cardiovascular and renal outcomes of systemic treatments for chronic plaque psoriasis.
- To evaluate the efficacy and safety profiles of different systemic immunomodulatory agents.
Main Methods:
- A network meta-analysis (NMA) of 68 randomized clinical trials (n=34,414 patients) was performed.
- Searched databases from inception through June 1, 2023.
- Assessed Psoriasis Area and Severity Index (PASI) 75/90, total cardiovascular events, major adverse cardiovascular events (MACE), and total renal events.
Main Results:
- Bimekizumab demonstrated superior PASI 75 rates and reduced total cardiovascular events compared to placebo.
- Ixekizumab showed higher PASI 90 rates but was associated with increased MACE versus placebo.
- Renal outcomes were comparable across treatment groups.
Conclusions:
- Bimekizumab exhibits superior efficacy and a favorable safety profile for plaque psoriasis treatment.
- Ixekizumab use requires caution due to a potential increase in cardiovascular risk.
- Further long-term safety data from non-randomized studies and postmarketing reports are needed.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
32
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
32
01:24Chronic Kidney Disease II: Clinical Manifestations
104
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
104
01:26Nephrotic Syndrome II : Assessment and Medical Management
24
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
24
01:26Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227